This leads to a phenomenon called “adaptive resistance” in tumors, wherein tumor cells adapt to evade immune surveillance by upregulating PD-L1 in response to IFN-γ secreted by tumor-infiltrating lymphocytes (TILs) [52,54]. This evidence concerns the gene IFNG and neoplasm.